Vietnam’s Ministry of Health (MOH) has recently issued a very important notification and new regulations relating to the implementation of Decree No. 36/2017/ND-CP (Decree 36) on medical device management. The key notification was issued under Official Dispatch No. 7165/BYT-TB-CT dated December 14, 2017 (Dispatch 7165). The new implementing guidelines for Decree 36 were issued under Circular No. 46/2017/TT-BYT dated December 15, 2017 (Circular 46). These developments are crucial to the registration regime for medical devices in Vietnam.
Dispatch 7165
While not relating to Class A medical devices (which include, for example bandages, wheelchairs, reusable surgical instruments, medical gloves, etc.), Dispatch 7165 provides specific guidance on Class B, C, and D devices, as well as in vitro diagnostic (IVD) biologicals. Class B medical devices include items such as blood centrifuges, diagnostic ultrasound scanners, and infusion cannulas, while Class C medical devices include items such as diagnostic X-ray equipment, electrosurgical units, and urethral stents. Class D medical devices include items such as absorbable sutures, arterioscopes, implantable infusion pumps, dental implants, etc.
A marketing authorization (MA) license for Class B, C, and D medical devices will only be required from January 1, 2019 onwards. This means that the MA regime for Class B, C, and D medical devices will be delayed for one year from the original date set forth under Decree 36. This delay is likely spurred on due to the imminent delays in registering massive amounts of medical devices that have never been registered before, especially when infrastructure and proper resources need to be bolstered among the registration teams/office of the MOH to handle the huge workload. The early deadlines to register all devices were not practicable and were over-ambitious goals.
From now until January 1, 2019, some specific interim regulations set forth under the new Official Dispatch are as follows:
Circular 46
Circular 46, which was just released, provides long-awaited implementing guidelines to Decree 36 and will enter into effect on February 1, 2018.
The Circular specifically states that Class C and D medical devices that are put into the human body are exempt from the requirement to submit summaries of clinical testing data and clinical testing research results. These medical devices include (1) medical devices in Annex I of the Circular (e.g., peritoneal dialysis catheters, cannulae, introducers, etc.), and (2) medical devices which are freely sold and have obtained certificates of free sale from a competent body of any of the countries and organizations which are set forth in Annex II of the Circular.
Class C or D IVD medical devices (e.g., HIV blood donor screening equipment, HIV blood diagnostic equipment, plasma bags, etc.) are also exempt from the requirement to submit test results if such medical devices have been freely sold and have obtained certificates of free sale from a competent body of any of the countries and organizations which are included in Annex II of the Circular. Annex II countries include Japan, Canada, the United States, and various European countries.
The Circular also includes a list (i.e., Annex III) of Class B, C, and D medical devices which may be traded like other normal goods, and imposes no requirements on the establishments trading them to declare their eligibility to trade in medical devices.
Additionally, the MOH issued guidance on presenting technical summaries, and requirements and terminology for Vietnamese to English translations for the LOA. A sample LOA is also promulgated under the Circular.
Technical summaries and English LOAs which were signed before the effective date of the Circular (February 1, 2018) will continue to be used; companies are not required to re-prepare these documents.